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Changes in the intestinal 
microbiota following the 
administration of azithromycin in a 
randomised placebo-controlled trial 
among infants in south India
Edward P. K. Parker1, Ira Praharaj  2, Jacob John2, Saravanakumar Puthupalayam Kaliappan  2, 
Beate Kampmann3,4, Gagandeep Kang2 & Nicholas C. Grassly1
Macrolides are among the most widely prescribed antibiotics worldwide. However, their impact 
on the gut’s bacterial microbiota remains uncertain. We characterised the intestinal microbiota in 
6–11 month-old infants in India who received a 3-day course of azithromycin or placebo during a 
randomised trial of oral poliovirus vaccine immunogenicity (CTRI/2014/05/004588). In 60 infants per 
study arm, we sequenced the V4 region of the bacterial 16S rRNA gene in stool samples collected 
before and 12 days after finishing treatment. We also tested for the presence of common bacterial, 
viral, and eukaryotic enteropathogens in the same samples using real-time PCR in a Taqman array card 
(TAC) format. Azithromycin induced a modest decline in microbiota richness and a shift in taxonomic 
composition driven by a reduction in the relative abundance of Proteobacteria and Verrucomicrobia 
(specifically Akkermansia muciniphila). The former phylum includes pathogenic strains of Escherichia 
coli and Campylobacter spp. that declined in prevalence based on the TAC assay. These findings differ 
from previous observations among older children and adults in Europe and North America, suggesting 
that the effects of azithromycin on the bacterial microbiota may be specific to the age and geographic 
setting of its recipients.
The use of antibiotics continues to rise globally. Numerous concerns have been raised regarding the long-term 
sequelae of this trend, including threats to populations, such as the emergence of antibiotic-resistant pathogens, 
and threats to individuals, such as an increased risk of metabolic disorders, asthma, and inflammatory bowel 
disease, among others1–3. Perturbations of the gut’s bacterial microbiota appear to be key to the long-term effects 
of antibiotic exposure. In particular, studies in mice have revealed that early-life treatment with a β-lactam or 
macrolide may lead to accelerated growth, delayed microbiota maturation, and a diminished capacity of the 
microbiota to respond to changes in diet4.
With upwards of 8 billion individual doses administered each year, macrolides such as azithromycin and 
clarithromycin are among the most widely prescribed antibiotics globally5. In a recent cohort of 2–7 year-old 
children in Finland, treatment with a macrolide within the preceding 6 months was associated with a reduction 
in the diversity and relative maturity of the bacterial microbiota, as well as an increase in macrolide resistance 
genes6. However, few previous studies have considered the influence of macrolide exposure on the composition of 
the bacterial microbiota within the context of placebo-controlled clinical trials using antibiotics. Moreover, given 
that significant geographic variation occurs in microbiota composition7, the influence of a given antibiotic on the 
gut’s bacterial community may differ markedly from population to population.
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We recently performed a randomised placebo-controlled trial in Vellore, India, to examine the impact of 
a 3-day course of oral azithromycin on the immune response to a subsequent dose of monovalent type 3 oral 
poliovirus vaccine among seronegative 6–11 month-old infants8. Antibiotic treatment significantly reduced the 
prevalence of potentially pathogenic intestinal bacteria as well as the levels of several faecal biomarkers of intes-
tinal inflammation and permeability, including calprotectin, myeloperoxidase, and α1-antitrypsin8. Here, we 
assess the extent to which azithromycin influenced the composition of the bacterial microbiota in these infants by 
sequencing the V4 region of the bacterial 16S rRNA gene in DNA extracted from stool and testing for the pres-
ence of specific pathogen gene targets using PCR in a TaqMan array card (TAC) format. In addition, we report on 
the impact of age on microbiota composition.
Results
The bacterial microbiota progresses towards a more ‘adult-like’ composition between 6 and 
11 months of age. We sequenced the V4 hypervariable region of the 16S rRNA gene in 120 infants, includ-
ing 60 azithromycin recipients and 60 placebo recipients. For each infant, we assessed stool samples collected 
before and 12 days after completion of a 3-day course of treatment (study days 0 and 14, respectively). We also 
included samples from 40 adults cohabiting with trial participants to provide a population-specific baseline of the 
mature (adult) bacterial microbiota. After quality filtering, we obtained an average of 14,685 (standard deviation 
2,386) sequences per sample across the 240 infant samples and 40 adult samples that were tested. These sequences 
spanned 820 operational taxonomic units (OTUs) with ≥97% nucleotide identity, of which 265 were present in 
infants and 677 were present in adults. Sequencing of amplicons from two mock communities revealed no notable 
biases in amplification efficiency beyond those previously identified for the V4-specific primers used in this study 
(Supplementary Results; Supplementary Fig. S1)9.
At baseline, the bacterial microbiota was characterised by a small number of dominant taxa, evident at genus 
level (Fig. 1a) and OTU level – in both infants and adults, the majority of OTUs made up only a small propor-
tion of the observed community (Supplementary Fig. S2). Combining across study arms, pre-treatment (day-
0) infant samples were significantly less diverse than adult samples (72.2 ± 14.7 [mean ± standard deviation] 
vs 249.8 ± 57.2 for OTU count and 2.7 ± 0.5 vs 4.6 ± 0.6 for Shannon index; Student’s t test, p values <0.001), 
and clustered separately from adult samples based on Unifrac distances, which quantify the overlap in sample 
composition based on the proportion of the phylogenetic tree that leads to OTUs present in one but not both 
samples (adonis, R2 of 0.297 and 0.375 for unweighted distances and distances weighted by OTU abundance, 
respectively; p values <0.001; Fig. 1c). With increasing infant age, we observed a significant increase in day-0 
Figure 1. Composition of the bacterial microbiota at enrolment. (a) Mean relative taxon abundance at 
phylum and genus level among day-0 infant samples (n = 120) and adult samples (n = 40). Genera with a mean 
relative abundance of >1% in infants are included. For categories labeled as ‘other’ we include genera below 
this abundance threshold, including 11 taxa with a mean abundance of >1% in adults. Overall, we observed 
125 genera, of which 89 were present in infants and 85 were present in adults. (b) Number of OTUs by age. (c) 
Unweighted Unifrac distances, visualised via principal coordinates analysis, for day-0 infant samples and adult 
samples. Abbreviations: m, months; OTU, 97%-identity operational taxonomic unit; PC, principal coordinate.
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OTU count (Spearman’s rho = 0.56, p < 0.001; Fig. 1b) and Shannon index (Spearman’s rho = 0.48, p < 0.001), 
and a decrease in mean Unifrac distance from adult samples (increasing ‘microbiota age’), reflecting a shift in 
composition towards a more ‘adult-like’ microbiota between 6 and 11 months of age (Spearman’s rho, −0.56 and 
−0.42 for unweighted and weighted Unifrac distances, respectively; p values < 0.001; Supplementary Fig. S3). The 
highest-ranking age-discriminatory taxa among infants, as determined by Spearman’s rho, included OTUs classi-
fied as Faecalibacterium prausnitzii, Lactobacillus ruminis, and Dorea formicigenerans (Supplementary Table S1) 
– all taxa that have been linked with microbiota maturation among infants in Bangladesh10.
Azithromycin decreases microbiota diversity via depletion of Proteobacteria and Akkermansia 
muciniphila. Of the 120 infants included in the microbiota subset, 114 completed the trial per protocol, of 
whom 56 received azithromycin. Among per-protocol infants, no significant differences in infant age, microbiota 
diversity, microbiota age, or taxon relative abundance distinguished azithromycin from placebo recipients at day 
0. After treatment (day 14), azithromycin recipients had a significantly lower OTU count than placebo recip-
ients (68.1 ± 15.4 vs 73.6 ± 13.7; linear regression, p = 0.027 for the effect of study arm after adjusting for age; 
Fig. 2a). A lower Shannon index was also evident in azithromycin versus placebo recipients, albeit non-significant 
(2.6 ± 0.5 vs 2.8 ± 0.5; linear regression, p = 0.087). Similar trends were observed when day-0 and day-14 sam-
ples within the azithromycin arm were compared in a longitudinal analysis (mean of 72.1 ± 14.1 OTUs on day 0 
versus 68.1 ± 15.4 on day 14; Wilcoxon’s test, p = 0.063; Shannon index of 2.7 ± 0.4 versus 2.6 ± 0.5, respectively; 
p = 0.155).
Based on Unifrac distances, we observed considerable overlap in microbiota composition between azithro-
mycin and placebo recipients at day 14 (Fig. 2b,c). Nonetheless, treatment (study arm) accounted for a small 
but significant proportion of variance within the Unifrac distance matrices (adonis, R2 of 0.020 and 0.022 for 
unweighted and weighted distances, respectively; p values < 0.05). Microbiota age was comparable in azithro-
mycin and placebo recipients at day 14 based either on unweighted Unifrac distances from adults (0.826 ± 0.042 
vs 0.821 ± 0.051; linear regression, p = 0.577 for the effect of study arm after adjusting for age) or weighted dis-
tances (0.598 ± 0.041 vs 0.593 ± 0.042; linear regression, p = 0.543; Supplementary Fig. S4) – findings that were 
corroborated by comparing day-0 and day-14 samples among azithromycin recipients in a longitudinal analysis 
(Wilcoxon’s test, p values > 0.05).
The day-0 and day-14 samples collected from each infant tended to cluster together based on Unifrac dis-
tances (Wilcoxon’s test, p values < 0.001 for comparisons of within-subject versus between-subject distances; 
Supplementary Fig. S5). When within-subject Unifrac distances were used as a measure of microbiota stabil-
ity, we observed an increase in community turnover (or decreased stability) in azithromycin compared with 
placebo recipients based on unweighted distances (0.485 ± 0.074 vs 0.446 ± 0.076; Wilcoxon’s test, p = 0.005; 
Supplementary Fig. S5B) but not on distances weighted by OTU abundance (0.230 ± 0.105 vs 0.218 ± 0.101; 
Wilcoxon’s test, p = 0.694; Supplementary Fig. S5D).
The observed changes in microbiota composition can be attributed primarily to decreases in the relative 
abundance of Proteobacteria and Verrucomicrobia in azithromycin compared with placebo recipients – at day 
14, these discrepancies were evident at all taxonomic ranks tested (phylum, class, genus, and OTU; Fig. 2d,e; 
Supplementary Table S2). Within the phylum Verrucomicrobia, all sequences mapped to a single OTU, classi-
fied as Akkermansia muciniphila. These changes in taxon relative abundance after azithromycin treatment were 
corroborated by the comparison of day-0 and day-14 samples within a longitudinal analysis (Supplementary 
Table S3), but this analysis also revealed an expansion of Firmicutes (driven in part by the genus Streptococcus) in 
azithromycin recipients on day 14.
Infants were frequently exposed to antibiotics other than the study intervention before and during this trial. 
Among infants included in our microbiota analysis who completed the study per protocol, 28/114 (25%) took 
antibiotics in the month before study enrolment, while 10/114 (9%) took non-intervention antibiotics between 
days 0 and 14. The antibiotic regimens – recorded in 31/38 (82%) of these instances – included β-lactams (17/31 
[55%]), sulphonamides (5/31 [16%]), and macrolides (3/31 [10%]), among others. Pre-enrolment antibiotic 
exposure was associated with a decrease in the number of OTUs present at day 0 (66.7 ± 14.9 vs 74.0 ± 13.9 in 
exposed and non-exposed infants, respectively; linear regression, p = 0.009 for the effect of antibiotic exposure 
after adjusting for age) and a corresponding decline in microbiota age based on unweighted Unifrac distances 
from adults, which were higher in exposed compared with non-exposed infants (0.837 ± 0.048 vs 0.814 ± 0.044; 
linear regression, p = 0.012). However, these discrepancies were no longer evident at day 14 (Supplementary 
Results; Supplementary Fig. S6).
The observed effects of azithromycin on microbiota composition (summarised in Table 1) were predominantly 
unchanged when infants who received non-intervention antibiotics were excluded. Effect sizes for comparisons 
of alpha and beta diversity at day 14 were very similar to those observed in the primary analyses (Supplementary 
Table S4), and a significant reduction in Proteobacteria and Verrucomicrobia abundance in azithromycin com-
pared with placebo recipients was apparent (Wilcoxon’s test, false discovery rate [FDR]-corrected p values 0.001 
and 0.002, respectively). The analyses were similarly unchanged when infants who failed to complete the study 
per protocol were included (data not shown).
Random Forests distinguish azithromycin from placebo recipients with modest predictive 
accuracy. To further elucidate the potential effects of azithromycin on microbiota composition, we used the 
Random Forests statistical-learning algorithm to classify infants according to study arm based on the relative 
abundances of OTUs on days 0 and 14. As expected, models lacked any discriminatory power at day 0 (median 
accuracy during cross-validation, 41.7%; interquartile range, 32.5–51.1%; baseline accuracy [wherein all infants 
are assigned to the majority class], 50.9%). Predictive accuracy was higher at day 14 (mean accuracy, 66.7%; 
interquartile range, 58.3–81.8%). This represents a rather meagre increase over baseline accuracy (50.9%), but 
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a significant improvement in fit compared with null models in which class labels (i.e., azithromycin/placebo) 
were randomly assigned to the input variables (p < 0.001). OTUs with the highest importance scores for accurate 
prediction of study arm generally overlapped with those exhibiting depleted relative abundances following azith-
romycin treatment (Fig. 3; Supplementary Tables S2 and S3).
Azithromycin has a therapeutic and prophylactic effect on bacterial enteropathogens. 
Asymptomatic carriage of intestinal pathogens detected by TAC was pervasive in this population. Indeed, 
in the study population as a whole, the proportion of infants harbouring ≥1 bacterial, viral, or eukaryotic 
Figure 2. Impact of azithromycin on the bacterial microbiota. (a) OTU count and Shannon index 
(mean ± standard error) according to study arm. (b) Unweighted and (c) weighted Unifrac distances between 
day-14 infant samples, visualised via principal coordinates analysis. Mean values for each principal coordinate 
are indicated by dotted lines. (d) OTU-level differences in relative taxon abundance at day 14 according to 
study arm. Bars display p values on a negative log10 scale. Comparisons with a p value of <0.05 prior to FDR 
correction are indicated. The tree was constructed from de novo OTU sequences spanning the V4 region of 
the 16S rRNA gene. Owing to the use of a relatively short (and hypervariable) segment of the 16S rRNA gene 
for tree construction, phyla do not always separate into discrete lineages. (e) Class-level differences in taxon 
abundance according to study arm. Mean relative abundance values for each study arm are indicated by 
horizontal lines. Values beyond the scale of the y-axis are indicated in red. *P < 0.05 (after FDR correction for 
abundance comparisons); **FDR-corrected P < 0.005. Abbreviations: AZ, azithromycin; OTU, 97%-identity 
operational taxonomic unit; Rel. abund., relative abundance; PC, principal coordinate; PL, placebo.
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enteropathogen was 662/704 (94%) and 636/704 (90%) at days 0 and 14, respectively. Meanwhile, diarrhoea was 
observed in 13/704 (2%) infants at each timepoint, and did not differ according to study arm at day 0 (7/347 [2%] 
vs 6/357 [2%] for azithromycin and placebo recipients, respectively; Fisher’s test, p = 0.786) or day 14 (3/347 [1%] 
vs 10/357 [3%]; Fisher’s test, p = 0.090). We previously demonstrated that azithromycin reduced the prevalence 
of bacterial enteropathogens in these infants at day 14 – an effect that was absent for viral and eukaryotic targets8.
To distinguish between the therapeutic versus prophylactic effects of antibiotic exposure, we assessed the 
impact of study arm on: (i) the proportion of individuals infected with a given enteropathogen on day 0 who 
retained this pathogen on day 14 (treatment); and (ii) the proportion of individuals uninfected at day 0 who 
became infected at day 14 (prophylaxis). Based on this approach, we found that azithromycin recipients were 
significantly less likely than placebo recipients to become colonised by bacterial pathogens – including entero-
aggregative Escherichia coli, enteropathogenic E. coli, and Campylobacter – between days 0 and 14 (Table 2). 
Enterotoxigenic E. coli (ETEC) was the only common bacterial pathogen to go against this trend, newly infecting 
Outcome Measure(s) Effect
Alpha diversity Number of OTUs/Shannon index OTU count ~7% lower in AZ than PL arm
Beta diversity Clustering based on unweighted/weighted Unifrac distances Significant clustering by study arm (R
2 of 0.02)
Taxon abundance Phylum-, class-, genus-, and OTU-level relative abundances
Decrease in several Proteobacteria strains and 
A. muc. in AZ arm
Microbiota age Average distance from adult samples (unweighted/weighted Unifrac) No significant association
Microbiota stability Distance between day-0 and day-14 samples (unweighted/weighted Unifrac)
Larger unweighted (but not weighted) distances 
in AZ arm
Other Predictive accuracy of Random Forest models based on OTU abundances
Predictive accuracy of 66.7% (baseline accuracy, 
50.9%)
Table 1. Summary of associations between azithromycin treatment and microbiota composition at day 14. 
Abbreviations: A. muc., Akkermansia muciniphila; AZ, azithromycin; OTU, 97%-identity operational taxonomic 
unit; PL, placebo.
Figure 3. Highest ranking taxa by Random Forest importance score for prediction of study arm after treatment 
with azithromycin. Importance scores were calculated based on the decrease in Gini impurity index associated 
with inclusion of each variable in a tree. Mean importance scores (±standard deviation) were calculated across 
200 cross-validation iterations of the Random Forests algorithm, with 5,000 trees per iteration.
www.nature.com/scientificreports/
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approximately 15% of infants in each study arm between days 0 and 14. Among infants infected on day 0, azith-
romycin consistently reduced the prevalence of bacterial enteropathogens (including ETEC) by day 14 (Table 2). 
Study arm did not significantly impact the rates of persistence or new infection for viral or eukaryotic enteropath-
ogens (Fisher’s test, p values > 0.05 for all comparison).
Discussion
Azithromycin inhibits the growth of numerous Gram-negative and Gram-positive bacteria, and is widely used to 
treat infections of the respiratory tract, urogenital tract, and skin11. Antibacterial mechanisms are varied, encom-
passing the inhibition of protein synthesis, the disruption of quorum sensing, and interference with adherence to 
host cells, among other11, 12. Activity extends to several common bacterial enteropathogens – in the present study, 
azithromycin had both a therapeutic effect (among infants infected on day 0) and a prophylactic effect (among 
uninfected infants) lasting for at least 12 days after the cessation of treatment. It is likely that the latter reflects, 
in part, the extended half-life of azithromycin in mucosal tissues (2–4 days)13. The extracellular release of azith-
romycin by macrophages and neutrophils (in which the macrolide achieves high concentrations) also appears 
to be dependent on the presence of bacteria at a site14. In spite of the significant reductions in pathogen burden 
observed among azithromycin recipients in this study using sensitive molecular detection methods, it is notable 
that the majority of infections occurred in the absence of diarrhoea and are thus of equivocal clinical significance. 
During a recent observational cohort study in Vellore, antibiotic treatment of diarrhoea was associated with a 
decrease in the median interval to a child’s next diarrhoeal episode15. Thus, the short-term reduction in pathogen 
burden observed following azithromycin treatment may not translate to a longer-term protective effect against 
diarrhoea.
Although the antimicrobial effects of azithromycin have been studied in relation to pathogenic bacteria, little 
is known regarding the impact of this drug on the bacterial microbiota as a whole, particularly during infancy. We 
observed a ~7% reduction in bacterial microbiota richness and a shift in composition 12 days after a 3-day course 
of treatment. Random Forest models based on microbiota composition were somewhat effective at distinguish-
ing infants according to study arm after azithromycin treatment, but their predictive accuracy was surprisingly 
limited given the recency of antibiotic exposure. The relatively modest treatment effect that we observed may in 
part reflect the normalisation of the microbiota after the cessation of antibiotics, as well as the fact that OTUs in 
several phyla (including Actinobacteria, Bacteroidetes, and Firmicutes) were largely unaffected by azithromy-
cin. The observed discrepancies in taxonomic composition according to study arm were driven primarily by the 
azithromycin-induced depletion of Proteobacteria (in particular the dominant genus Escherichia) and A. mucin-
iphila (phylum Verrucomicrobia).
Our results differ from recent findings from Europe and North America regarding the impact of mac-
rolides on microbiota composition. Korpela et al.6 observed a significant decrease in the relative abundance of 
Actinobacteria and a corresponding increase in Proteobacteria and Bacteroidetes among 2–7 year-old Finnish 
children exposed to azithromycin or clarithromycin within the preceding 6 months (although in agreement 
with our study an increased abundance of the genus Streptococcus in response to macrolide exposure was 
also reported). Meanwhile, Abeles et al.16 documented the depletion of Erysipelotrichaceae, Veillonellaceae, 
and Clostridiales (all members of the phylum Firmicutes) among US adults following a 3- or 7-day course of 
azithromycin as opposed to placebo. A. muciniphila is a mucin-degrading species of Gram-negative bacteria 
that has been suggested to play an important role in adipose tissue homeostasis17 and prevention of intestinal 
inflammation18. An increased abundance of this taxon has been observed following the treatment of adults with 
a range of non-macrolide antibiotic regimens19 and of mice with the veterinary macrolide tylosin4. However, 
while we observed A. muciniphila in 20% of azithromycin recipients on day 0, it was entirely absent from the 
post-treatment samples of these infants. Notably, these changes occurred in conjunction with a decrease in the 
levels of several faecal biomarkers of intestinal inflammation8.
The discord between previous findings and our own likely reflects discrepancies in trial setting and age of 
participants – both of which markedly alter the baseline composition of the microbiota upon which azithromycin 
has the potential to act – as well as time since antibiotic exposure. Indeed, the phylum Proteobacteria had a mean 
Pathogen
Prevalence 
on day 0, n 
(%)
Therapy: proportion of day 0 infections retained 
on day 14, n/N (%)
Prophylaxis: prevalence on day 14 among 
infants uninfected on day 0, n/N (%)
Placebo Azithromycin p Placebo Azithromycin p
≥1 Bacteria 625 (88.8) 288/317 (90.9) 209/308 (67.9) <0.001 29/40 (72.5) 16/39 (41.0) 0.006
EAEC 514 (73.0) 215/254 (84.6) 116/260 (44.6) <0.001 52/103 (50.5) 20/87 (23.0) <0.001
EPEC 292 (41.5) 77/146 (52.7) 56/146 (38.4) 0.019 80/211 (37.9) 44/201 (21.9) <0.001
ETEC 125 (17.8) 13/54 (24.1) 7/71 (9.9) 0.047 44/303 (14.5) 40/276 (14.5) 1.000
Campylobacter 161 (22.9) 40/85 (47.1) 12/76 (15.8) <0.001 47/272 (17.3) 13/271 (4.8) <0.001
Bacteroides fragilis 63 (8.9) 22/31 (71.0) 14/32 (43.8) 0.042 12/326 (3.7) 7/315 (2.2) 0.276
Clostridium difficile 19 (2.7) 5/12 (41.7) 1/7 (14.3) 0.333 4/345 (1.2) 6/340 (1.8) 0.543
Salmonella 19 (2.7) 1/9 (11.1) 0/10 (0.0) 0.474 3/348 (0.9) 1/337 (0.3) 0.624
Table 2. Therapeutic versus prophylactic effects of azithromycin. Prevalence was compared according to 
study arm using Fisher’s exact test. Bacterial enteropathogens present in at least 2% of infants on day 0 are 
included. Abbreviations: EAEC, enteroaggregative Escherichia coli; EPEC, enteropathogenic E. coli; ETEC, 
enterotoxigenic E. coli.
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relative abundance of 17% at baseline in the present study, but had a low abundance (<5%) in the majority of 
children in the study by Korpela et al.6. This phylum also contains enteroaggregative E. coli, Campylobacter, and 
several of the other bacterial enteropathogens that declined in prevalence following azithromycin treatment in 
the present study. In addition to differences in baseline composition of the bacterial microbiota, the prevalence of 
antibiotic resistance genes (the ‘resistome’) may differ markedly among populations20. These differences may play 
an important role in shaping the effect of antibiotic exposure on microbiota composition.
Azithromycin did not significantly influence microbiota age, which we assessed among infant samples by 
measuring their mean Unifrac distance from adult samples. Previous findings regarding the impact of antibiotics 
on microbiota maturity have been mixed – while antibiotic exposure within the preceding 7 days did not influ-
ence relative microbiota maturity among infants in Bangladesh10, a decrease in microbiota maturity was apparent 
up to 2 years after macrolide exposure in the aforementioned Finnish cohort6. Similarly, early-life antibiotic expo-
sure in mice resulted in delayed maturation of the bacterial microbiota4. Given that the effects of azithromycin 
were assessed just 12 days after the cessation of treatment, we cannot rule out a longer-term impact of antibiotic 
exposure on the developmental trajectory of the microbiota in the present study population.
Several limitations of this work should be acknowledged. Biases in amplification efficiency and discriminatory 
power arise when profiling the bacterial microbiota using amplicon sequencing21. Although these could have 
been exacerbated in the present study through the use of non-degenerate primers rather than degenerate primers 
that target somewhat more bacterial taxa (such as those used by Caporaso et al.22), the taxonomic distributions we 
obtained from mock communities of known composition were largely consistent with those previously attained 
using degenerate V4-specific primers9. Perhaps more importantly, our sequencing pipeline captures changes in 
the relative (rather than absolute) abundance of bacterial taxa at a given sequencing depth. We may therefore have 
failed to describe changes in absolute abundance of the bacterial microbiota in azithromycin recipients. As noted 
above, the short-term effects of azithromycin captured in our study may differ from the longer-term sequelae of 
antibiotic exposure6, 23. Finally, by focusing on changes in microbiota diversity and composition of the bacterial 
microbiota, we may have failed to capture changes in the functional capacity of the microbiome following azith-
romycin treatment, including the potential emergence of macrolide resistance24 and the alteration of metabolic 
phenotypes4, 25.
Overall, our findings revealed a modest effect of azithromycin on the composition of the bacterial microbiota 
among 6–11 month-old infants in south India. Although azithromycin brought about a decrease in microbiota 
diversity and a reduction in the abundance of several taxa, antibiotic treatment did not appear to influence the 
relative maturity of the bacterial microbiota. In addition, the bacterial taxa most affected by azithromycin differed 
markedly from those identified in previous studies of macrolide exposure in Europe and North America. Thus, 
changes in composition of the bacterial microbiota following treatment with a given antibiotic appear to be highly 
specific to the age and geographic setting of its recipients.
Methods
Study population. A full description of the design, laboratory methods, and primary outcomes of the 
study has previously been published8. Infants were randomised 1:1 to receive a 3-day course of azithromycin 
(administered once daily at a dose of 10 mg/kg) or placebo (comprising a syrup of matching colour and taste), 
starting on study day 0. A subset of 120 infants (60 per study arm) out of the first 300 enrolled in the study were 
selected at random for assessment of the bacterial microbiota. These infants were also assessed for the presence 
of multiple potentially pathogenic bacteria, viruses, and eukaryotes in stool samples via real-time PCR using 
TACs, as previously described8. The trial complied with good clinical practice guidelines and the ethical prin-
ciples of the Declaration of Helsinki. Written informed consent for enrolment was obtained from a parent or 
caregiver. The study was approved by the Institutional Review Board of the Christian Medical College and the 
Drugs Controller General of India, and was registered with the Clinical Trials Registry India on 09 May 2014 
(CTRI/2014/05/004588).
Characterisation of the 16S rRNA microbiota. Full details of the laboratory and bioinformatic 
methods adopted in this study are provided in the Supplementary Materials. Briefly, DNA was extracted 
from 200 mg of stool, and the V4 region of the 16S rRNA gene subsequently amplified using primers 515F 
(5′-GTGCCAGCAGCCGCGGTAA-3′) and 806R (5′-GGACTACCAGGGTATCTAAT-3′). Purified PCR 
products were sequenced in a single Illumina MiSeq run that also included one no-template PCR control, 14 
no-template extraction controls, and PCR products amplified from two mock communities obtained from BEI 
resources (Manassas, USA). After sequencing, reads were assembled into contigs using FLASH26 and analysed 
using QIIME (MacQIIME version 1.8.0). Contigs were quality-filtered27, then clustered de novo into OTUs with 
≥97% nucleotide identity using a modified version of the ‘denovo.sh’ pipeline published by Nelson et al.9. All 
analyses were performed at a rarefaction depth of 7,500 sequences per sample.
Baseline composition of the bacterial microbiota. OTU count and Shannon index were compared 
between day-0 infant samples and adult samples using Student’s t test. Unifrac distances between these samples, 
either weighted by taxon abundance (weighted Unifrac) or unweighted (unweighted Unifrac)28, were visualised 
using principal coordinates analysis, and cluster significance assessed using the adonis function (in the R package 
vegan29) with 9,999 permutations. We used the mean Unifrac distance of each infant sample from non-cohabiting 
adults as an indicator of microbiota age. Two adult samples were excluded from calculations of infant microbiota 
age as they had substantially lower diversity than the remaining adult samples (Fig. 1a) and clustered with infant 
samples based on unweighted Unifrac distances (Fig. 1b). Changes in microbiota diversity, microbiota age, and 
OTU relative abundances with respect to infant age were assessed in day-0 samples using Spearman’s rho.
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Impact of azithromycin on the bacterial microbiota. Analyses regarding the effect of azithromycin on 
microbiota composition were restricted to individuals who completed the study per protocol (see Supplementary 
Materials for a summary of protocol deviations). Infant age at day 0 was compared according to study arm using 
Wilcoxon’s rank sum test. The effect of azithromycin on OTU count, Shannon index, and microbiota age (as con-
tinuous dependent variables) was assessed in cross-sectional analyses at days 0 and 14 via linear regression (with 
study arm as a categorical explanatory variable and age included as a covariate). We also performed longitudinal 
analyses to compare these metrics between day-0 and day-14 samples in each study arm using Wilcoxon’s signed 
rank test for paired data. Unifrac distances between infant samples were visualised using principal coordinates 
analysis and cluster significance assessed using adonis. Age was included prior to study arm when implementing 
adonis and significance determined based on sequential sums of squares.
Phylum-, class-, genus-, and OTU-level discrepancies in taxon relative abundance were compared between 
study arms using Wilcoxon’s rank sum test (cross-sectional analyses), and between day-0 and day-14 samples 
in each arm using Wilcoxon’s signed rank test (longitudinal analyses). Taxa were assessed if they were pres-
ent in at least 2% of samples being compared. To account for multiple comparisons, p values were adjusted by 
Benjamini–Hochberg FDR correction30, applied separately at each taxonomic rank for a given comparison. OTUs 
associated with study arm were visualised using Interactive Tree of Life31. Within-subject distances (between 
samples collected from the same infant at days 0 and 14) were compared with between-subject Unifrac dis-
tances (comprising the average Unifrac distance of each day-0 sample from the day-14 samples collected from 
other infants) using Wilcoxon’s rank sum test. The effect of azithromycin on within-subject Unifrac distances was 
assessed using Wilcoxon’s rank sum test. For comparisons of taxon abundance, we report on any associations with 
an FDR-corrected p value of <0.15. For all other comparisons, p values of <0.05 were considered statistically 
significant.
Impact of non-intervention antibiotics. Exposure to antibiotics in the month before enrolment was 
recorded on day 0 and use of non-intervention antibiotic post-enrolment was recorded on day 14 through inter-
view of the caregiver by the study physician. The name of the antibiotic was recorded where possible from the 
used medicine container or prescription. The effect of pre-enrolment antibiotic exposure on OTU count, Shannon 
index, microbiota age, sample clustering based on Unifrac distances, and taxon relative abundances was assessed 
on days 0 and 14 using the methods described above for cross-sectional analyses of study arm (see Supplementary 
Materials for additional details). The potential association between non-intervention antibiotic use and study arm 
was assessed using Fisher’s exact test.
Random Forests. Random Forest models were implemented in the R package randomForest to discriminate 
infants according to study arm based on the composition of their bacterial microbiota32. A table of OTU relative 
abundances served as input for the models. Separate analyses were carried out for day-0 and day-14 samples. 
For each analysis, out-of-bag error rates and variable importance scores (based on Gini index) were determined 
across 20 cycles of 10-fold cross-validation (200 iterations in total), with 5,000 trees per iteration and all other 
parameters at their default values. Cross-validation was implemented in the R package crossval33. Significance of 
the model fit was assessed by generating 999 null models in which study arm labels were randomly assigned to 
the input variables and determining the proportion of null models with an out-of-bag error rate smaller than the 
median error rate of the fitted models.
Enteropathogen prevalence. We assessed the impact of study arm on the prevalence of novel infections 
(absent on day 0, present on day 14) or persistent infections (present on days 0 and 14) based on TAC data, and 
concurrent diarrhoea, using Fisher’s exact test.
Sensitivity analyses. We performed sensitivity analyses in which: (i) the effect of azithromycin on microbi-
ota composition was assessed among infants with no exposure to non-intervention antibiotics; and (ii) compar-
isons were performed for all infants providing stool samples without restriction to per-protocol infants. In each 
case, we compared OTU count, Shannon index, microbiota age, and phylum-level taxon relative abundances 
according to study arm in day-14 samples using the cross-sectional analysis methods described above.
Data availability. 16S rRNA sequences generated from faecal samples have been deposited in the European 
Nucleotide Archive (accession number PRJEB20773). An OTU table obtained after sequence assembly, quality 
filtering, chimera checking, taxonomic assignment, and minimum abundance filtering is provided in biom format 
in the Supplementary Materials, as is a file containing relevant metadata.
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